Compugen investors sell 509,436 shares, keep 5.96% ownership interest

By Lisa Kerner

Charlotte, N.C., July 1 - A group of Compugen Ltd. investors led by Clal Biotechnology Industries Ltd. sold 509,436 shares between May 11 and June 23 priced from $0.91 to $1.69, according to a schedule 13D/A filed on Wednesday with the Securities and Exchange Commission.

The investors beneficially own 1,698,021 shares, or 5.96%, of the company's outstanding stock.

Compugen is a biotechnology discovery company focused on therapeutic and diagnostic products. The company is based in Tel Aviv, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.